A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing.
Benderski K, Schneider P, Kordeves P, Fichter M, Schunke J, De Lorenzi F, Durak F, Schrörs B, Akilli Ö, Kiessling F, Bros M, Diken M, Grabbe S, Schattenberg JM, Lammers T, Sofias AM, Kaps L.
Benderski K, et al. Among authors: schneider p.
Pharmacol Res. 2025 Jan;211:107560. doi: 10.1016/j.phrs.2024.107560. Epub 2024 Dec 25.
Pharmacol Res. 2025.
PMID: 39730106
Free article.